Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | MRD status in guiding drug development and approval

Francesca Gay • 15 Sep 2019
IMW 2019
Multiple Myeloma

Francesca Gay, MD, of University of Turin, Turin, Italy, talks about MRD negativity in guiding drug development and approval. Recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Francesca Gay

1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020
1:06
MRD evaluation by MFC and NGS for MM
Francesca Gay • 7 Dec 2019

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals